Estudo randomizado fase 2 | Eficácia de mFOLFIRINOX pré-operatório vs. mFOLFIRINOX com radioterapia hipofracionada para adenocarcinoma ressecável limítrofe do pâncreas.
18 Jul, 2022 | 13:16hEfficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the PancreasThe A021501 Phase 2 Randomized Clinical Trial – JAMA Oncology (gratuito por tempo limitado)
Editorial: The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer – JAMA (gratuito por tempo limitado)
Comunicado de imprensa: Preoperative combination chemotherapy improved survival in patients with pancreatic cancer – The University of Texas MD Anderson Cancer Center
Comentário no Twitter
Ph 2 trial of 126 pts w/borderline resectable pancreatic ductal adenoCa shows 18 mo OS after neoadjuvant mFOLFIRINOX of 66.7%, favorable vs. historical data; 18m OS if mFOLFORINOX then hypofract RT is 47.3%, if chemo then pancreatectomy is 87.5%. https://t.co/wOMNrTOAzm
— JAMA Oncology (@JAMAOnc) July 14, 2022